Evgen Pharma talks through clinical milestones and financial results from its 2022 full-year report mel | 16 June 2022
Evgen Pharma presents 2022 clinical trials plans and progress with US and UK regulators mel | 26 January 2022
TheraCryf portfolio update on core field of cancer, ‘the R&D is entirely on plan and on budget’ steve | 22 July 2021
TheraCryf updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug steve | 26 January 2021
TheraCryf have ‘many shots at goal’, solving unmet needs in the pharmaceutical industry steve | 16 December 2020
